IGFBP3 Enhances Treatment Outcome and Predicts Favorable Prognosis in ABC-DLBCL

Table 3

Univariate and multivariate Cox regression analysis of OS from GEO.

Variables	Univariate Cox			Multivariate Cox
	HR	95% CI		HR	95% CI
IGFBP3 expression (high vs low)	0.604	0.365–0.997	0.049	0.722	0.367–1.419	0.345
Age (>60 vs ≤60)	1.588	1.067–2.363	0.023	1.508	0.664–3.427	0.327
Sex (male vs female)	0.869	0.609–1.240	0.439
Stage (III + IV vs I + II)	2.019	1.365–2.986	<0.001	1.778	0.329–1.837	0.567
Extranodal infiltration (>1 vs ≤1)	2.191	1.485–3.234	<0.001	1.069	0.327–3.500	0.912
ECOG score (>1 vs ≤1)	2.779	1.901–4.062	<0.001	2.952	1.334–6.531	0.008
LDH (elevated vs normal)	1.955	1.264–3.024	0.003	1.837	0.298–2.354	0.736
IPI score (>2 vs ≤2)	3.615	2.168–6.026	<0.001	2.368	0.606–9.261	0.215
Treatment response (non-CR vs CR)	1.581	0.953–2.624	0.076	1.309	0.522–3.283	0.566

ECOG score, eastern cooperative oncology group score; LDH, lactate dehydrogenase; CR, complete response; non-CR, partial response, stable disease, progressive disease; bold, significant difference.